An analysis published July 4th explores Viking Therapeutics' stock potential to reach $50. Viking Therapeutics' lead candidate, VK2735, drives optimism. This weight-loss drug is currently in late-stage trials. The drug targets a market expected to approach $100 billion. Eli Lilly and Novo Nordisk currently dominate this space.
The bull case relies on positive data from ongoing and upcoming trials. These trials include both injectable and oral versions of VK2735. Strong phase 2 data previously caused the stock to soar over 100% in a single session. This indicates high investor sensitivity to clinical news. The bear case highlights the challenge of competing with established pharmaceutical giants. Eli Lilly and Novo Nordisk possess vast resources for marketing and development.